Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879), and Stop Superbugs Act (S.5237).
Client expense: $50,000 · Firm income: Not reported
Referred to the House Committee on Foreign Affairs.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352/S.4875 119th Congress),Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445/S.4283), SUPERBUGS Act, H.R.7879, 119th Congress.
Client expense: $290,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29 FOLLOW UP ON ALTERNATIVE FUNDING PROGRAMS AND IMPORTATION OF DRUGS; CFF SENDS LETTER TO FDA AND CDER REGARDING A CITIZEN PETITION CONCERNING ALTERNATIVE FUNDING PROGRAMS (AFPS) COMMENTS ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK; CFF SUBMITS COMMENTS TO THE FDA ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK, URGING A FLEXIBLE APPROACH TO SUPPORT THE DEVELOPMENT OF GENE EDITING AND OTHER THERAPIES FOR PEOPLE WITH ULTRA-RARE MUTATIONS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2026 · second_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352 119th Congress) Senate PASTEUR Act not yet introduced in 119th Congress, Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445)not yet introduced in Senate, SUPERBUGS Act, H.R.7879, 119th Congress.
Client expense: $169,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS SURROUNDING FY2027 APPROPRIATIONS; PROVISIONS RELATED TO NATIONAL INSTITUTE OF HEALTH AND FOOD AND DRUG ADMINISTRATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE
Client expense: $250,000 · Firm income: Not reported
2026 · first_quarter · Health Issues
H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING THE ENHANCED ADVANCED PREMIUM TAX CREDIT EXPIRATION AND EXTENSION GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HEALTH DEDUCTIBLE HEALTH PLANS PAIRED WITH HEALTH SPENDING ACCOUNTS GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH PPC 2027 NOTICE OF BENEFIT AND PAYMENT PARAMETERS; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN COMMENTS ON 2027 HHS NOTICE OF BENEFIT AND PAYMENT PARAMETERS PPC LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES ON H.R. 1 IMPLEMENTATION; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN LETTER TO CMS EXPRESSING CONCERNS AND ASKING FOR FURTHER CLARIFICATION ON PIECES OF H.R. 1 IMPLEMENTATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE